Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types

Blood

Volumn 122, Issue 2, 2013, Pages 161-169

  Ou, Xuan ^a   O'Leary, Heather A ^a   Broxmeyer, Hal E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; EOTAXIN 3; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; ERYTHROPOIETIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 5; RANTES; STROMAL CELL DERIVED FACTOR 1; PROTEIN;

CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CHEMOTAXIS; ENZYME ACTIVITY; HEMATOPOIETIC STEM CELL; HUMAN; LEUKOCYTE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; ANIMAL; BIOLOGICAL MODEL; CELL LINEAGE; CELL MOTION; CYTOLOGY; EMBRYONIC STEM CELL; HEMATOPOIESIS; IMMUNOLOGY; LYMPHOID PROGENITOR CELL; METABOLISM; MYELOID PROGENITOR CELL; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL MOVEMENT; DIPEPTIDYL PEPTIDASE 4; EMBRYONIC STEM CELLS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEUKOCYTES; LYMPHOID PROGENITOR CELLS; MODELS, BIOLOGICAL; MYELOID PROGENITOR CELLS; PROTEINS;

EID: 84883419226     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-487470     Document Type: Review

References (81)

1. Shaheen M, Broxmeyer HE. The humoral regulation of hematopoiesis. In: Benz EJ Jr, Shattil SJ, Furie B, et al, eds. Hematology: Basic Principles and Practice Hoffman, R. 5th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2009:253-275
2. Shaheen M, Broxmeyer HE. Hematopoietic cytokines and growth factors. In: Broxmeyer HE, ed. Cord Blood Biology, Transplantation, Banking, and Regulation. Bethesda, MD: AABB Press; 2011:35-74.
3. Shaheen M, Broxmeyer HE. Principles of Cytokine Signaling. In: Benz EJ Jr, Silberstein LE, Heslop H, Weitz J, Anastasi J, eds. Hematology: Basic Principles and Practice Hoffman, R, 6th ed. Philadelphia, PA: Elsevier Churchill Livingston; 2012:136-146
4. Christopherson KW II, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol. 2002;169(12):7000-7008. (Pubitemid 36899288)
5. Christopherson KW II, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004;305(5686):1000-1003. (Pubitemid 39071774)
6. Broxmeyer HE, Hoggatt J, O'Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med. 2012;18(12):1786-1796.
7. Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie. 1966;7(3):197-201.
8. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol. 2003;10(1):19-25. (Pubitemid 36034172)
9. Martin RA, Cleary DL, Guido DM, Zurcher-Neely HA, Kubiak TM. Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr or Val. Extended DPP-IV substrate specificity? Biochim Biophys Acta. 1993;1164(3):252-260. (Pubitemid 23234575)
10. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209-294. (Pubitemid 36775376)
11. Solau-Gervais E, Zerimech F, Lemaire R, Fontaine C, Huet G, Flipo RM. Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis. Scand J Rheumatol. 2007;36(5):373-377. (Pubitemid 350034815)
12. Lambeir AM, Díaz Pereira JF, Chacón P, et al. A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. Biochim Biophys Acta. 1997;1340(2):215-226. (Pubitemid 27301426)
13. Grim M, Carlson BM. Alkaline phosphatase and dipeptidylpeptidase IV staining of tissue components of skeletal muscle: a comparative study. J Histochem Cytochem. 1990;38(12):1907-1912. (Pubitemid 20382408)
14. Guo Y, Hangoc G, Bian H, Pelus LM, Broxmeyer HE. SDF-1/CXCL12 enhances survival and chemotaxis of murine embryonic stem cells and production of primitive and definitive hematopoietic progenitor cells. Stem Cells. 2005;23(9):1324-1332. (Pubitemid 41504920)
15. Campbell TB, Broxmeyer HE. CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation. Front Biosci. 2008;13:1795-1805. (Pubitemid 351599733)
16. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251-254.
17. Preller V, Gerber A, Wrenger S, et al. TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol. 2007;178(7):4632-4640. (Pubitemid 46492416)
18. Ellingsen T, Hornung N, Møller BK, Hjelm-Poulsen J, Stengaard-Pedersen K. In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. Scand J Immunol. 2007;66(4):451-457. (Pubitemid 47394557)
19. Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg. 2012;41(5):1166-1173.
20. Wieland E, Shipkova M, Martius Y, Hasche G, Klett C, Bolley R, Olbricht CJ. Association between pharmacodynamic biomarkers and clinical events in the early phase after kidney transplantation: a single-center pilot study. Ther Drug Monit. 2011;33(3):341-349.
21. Jungraithmayr W, Oberreiter B, De Meester I, et al. The effect of organ-specific CD26/DPP IV enzymatic activity inhibitor-preconditioning on acute pulmonary allograft rejection. Transplantation. 2009;88(4):478-485.
22. Korom S, de Meester I, Belyaev A, Schmidbauer G, Schwemmle K. CD26/DPP IV in experimental and clinical organ transplantation. Adv Exp Med Biol. 2003;524:133-143. (Pubitemid 36570820)
23. Korom S, De Meester I, Coito AJ, et al. CD26/DPP IV-mediated modulation of acute rejection. Transplant Proc. 1999;31(1-2):873. (Pubitemid 29127719)
24. Khurana S, Margamuljana L, Joseph C, Schouteden S, Buckley SM, Verfaillie CM. Glypican-3 mediated inhibition of CD26 by TFPI: a novel mechanism in hematopoietic stem cell homing and maintenance. Blood. 2013;121(14):2587-2595
25. Laudes M, Oberhauser F, Schulte DM, et al. Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects. Exp Clin Endocrinol Diabetes. 2010;118(8):473-477.
26. Tian C, Bagley J, Forman D, Iacomini J. Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors. Gene Ther. 2006;13(7):652-658.
27. Wyss BK, Donnelly AF, Zhou D, Sinn AL, Pollok KE, Goebel WS. Enhanced homing and engraftment of fresh but not ex vivo cultured murine marrow cells in submyeloablated hosts following CD26 inhibition by Diprotin A. Exp Hematol. 2009;37(7):814-823.
28. Peranteau WH, Endo M, Adibe OO, Merchant A, Zoltick PW, Flake AW. CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation. Blood. 2006;108(13):4268-4274. (Pubitemid 44913303)
29. Campbell TB, Hangoc G, Liu Y, Pollok K, Broxmeyer HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev. 2007;16(3):347-354.
30. Christopherson KW 2nd, Paganessi LA, Napier S, Porecha NK. CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev. 2007;16(3):355-360. (Pubitemid 47016220)
31. Kawai T, Choi U, Liu PC, Whiting-Theobald NL, Linton GF, Malech HL. Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. Stem Cells Dev. 2007;16(3):361-370. (Pubitemid 47016221)
32. Christopherson KW, Cooper S, Hangoc G, Broxmeyer HE. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol. 2003;31(11):1126-1134. (Pubitemid 37329758)
33. Christopherson KW II, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood. 2003;101(12):4680-4686. (Pubitemid 36857720)
34. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(11):4612-4619. (Pubitemid 44833446)
35. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46(8):876-886. (Pubitemid 44050824)
36. Farag SS, Srivastava S, Messina-Graham S, et al. In-vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev. 2013;22(7):1007-1015.
37. Parker MH, Loretz C, Tyler AE, Snider L, Storb R, Tapscott SJ. Inhibition of CD26/DPP-IV enhances donor muscle cell engraftment and stimulates sustained donor cell proliferation. Skelet Muscle. 2012;2(1):4.
38. Blanchet X, Langer M, Weber C, Koenen RR, von Hundelshausen P. Touch of chemokines. Front Immunol. 2012;3:175.
39. Proost P, Struyf S, Schols D, et al. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem. 1999;274(7):3988-3993.
40. Struyf S, Proost P, Sozzani S, et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol. 1998;161(6):2672-2675. (Pubitemid 28425683)
41. Proost P, Struyf S, Couvreur M, et al. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J Immunol. 1998;160(8):4034-4041. (Pubitemid 28176113)
42. Struyf S, Proost P, Schols D, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol. 1999;162(8):4903-4909. (Pubitemid 29314895)
43. Wrenger S, Reinhold D, Hoffmann T, et al. The N-terminal X-X-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells. FEBS Lett. 1996;383(3):145-149. (Pubitemid 26104050)
44. Smith AG, Heath JK, Donaldson DD, et al. Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature. 1988;336(6200):688-690. (Pubitemid 19007952)
45. Xu RH, Peck RM, Li DS, Feng X, Ludwig T, Thomson JA. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat Methods. 2005;2(3):185-190. (Pubitemid 41122125)
46. Yu P, Pan G, Yu J, Thomson JA. FGF2 sustains NANOG and switches the outcome of BMP4-induced human embryonic stem cell differentiation. Cell Stem Cell. 2011;8(3):326-334.
47. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676. (Pubitemid 44233629)
48. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-872. (Pubitemid 350138099)
49. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917-1920.
50. Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012;10(6):678-684.
51. Broxmeyer HE. Will iPS cells enhance therapeutic applicability of cord blood cells and banking? Cell Stem Cell. 2010;6(1):21-24.
52. Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood. 2011;117(18):4773-4777.
53. Broxmeyer HE. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med. 2013;210(2):205-208.
54. Broxmeyer HE, Campbell TB, Cooper S, and Hangoc G. Inhibition/Depletion of CD26/DPPIV Enhances Survival Promoting Activity of SDF-1/CXCL12 and Myelosuppressive Activities of Inhibitory Chemokines on Hematopoietic Progenitor Cells. Blood. 2007;110(Suppl Part 1):188A (abstract #610). 2007.
55. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126-1131.
56. Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem. 1997;272(34):21201-21206. (Pubitemid 27373982)
57. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340-2350. (Pubitemid 351653542)
58. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402-7405.
59. Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650-19655. (Pubitemid 23270754)
60. López de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem. 2003;278(12):10195-10200. (Pubitemid 36800279)
61. Ochiai H, Okada S, Saito A, et al. Inhibition of insulin-like growth factor-1 (IGF-1) expression by prolonged transforming growth factor-β1 (TGF-β1) administration suppresses osteoblast differentiation. J Biol Chem. 2012;287(27):22654-22661.
62. Nagineni CN, Samuel W, Nagineni S, et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol. 2003;197(3):453-462. (Pubitemid 37487044)
63. Renner U, Lohrer P, Schaaf L, et al. Transforming growth factor-beta stimulates vascular endothelial growth factor production by folliculostellate pituitary cells. Endocrinology. 2002;143(10):3759-3765. (Pubitemid 35244353)
64. Zhou X, Hu H, Balzar S, Trudeau JB, Wenzel SE. MAPK regulation of IL-4/IL-13 receptors contributes to the synergistic increase in CCL11/eotaxin-1 in response to TGF-β1 and IL-13 in human airway fibroblasts. J Immunol. 2012;188(12):6046-6054.
65. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841-846. (Pubitemid 37351468)
66. Stier S, Ko Y, Forkert R, et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med. 2005;201(11):1781-1791. (Pubitemid 41002897)
67. Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005;106(4):1232-1239. (Pubitemid 41129584)
68. Rankin EB, Wu C, Khatri R, et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012;149(1):63-74.
69. Zhu J, Garrett R, Jung Y, et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood. 2007;109(9):3706-3712. (Pubitemid 46641719)
70. Huber BC, Brunner S, Segeth A, et al. Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart. Cardiovasc Res. 2011;90(3):529-537.
71. Grassinger J, Haylock DN, Storan MJ, et al. Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with alpha9beta1 and alpha4beta1 integrins. Blood. 2009;114(1):49-59.
72. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012;481(7382):457-462.
73. Istvanffy R, Kröger M, Eckl C, et al. Stromal pleiotrophin regulates repopulation behavior of hematopoietic stem cells. Blood. 2011;118(10):2712- 2722.
74. Butler JM, Nolan DJ, Vertes EL, et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell. 2010;6(3):251-264.
75. Hooper AT, Butler JM, Nolan DJ, et al. Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. Cell Stem Cell. 2009;4(3):263-274.
76. Sharifi BG, Zeng Z, Wang L, et al. Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26(6):1273-1280. (Pubitemid 44305370)
77. George AL, Bangalore-Prakash P, Rajoria S, et al. Endothelial progenitor cell biology in disease and tissue regeneration. J Hematol Oncol. 2011;4:24.
78. Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 2008;22(5):559-574. (Pubitemid 351342429)
79. Salcedo R, Young HA, Ponce ML, et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol. 2001;166(12):7571-7578. (Pubitemid 32525638)
80. Matheeussen V, Jungraithmayr W, De Meester I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol Ther. 2012;136(3):267-282.
81. O'Leary HA.*, Ou X*, Broxmeyer HE. The role of dipeptidyl peptidase 4 (DPP4) in hematopoiesis and transplantation. Curr Opin Hematol. 2013; [Epub ahead of print]